<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085873</url>
  </required_header>
  <id_info>
    <org_study_id>2020-CHITS-002</org_study_id>
    <secondary_id>2021-001961-19</secondary_id>
    <nct_id>NCT05085873</nct_id>
  </id_info>
  <brief_title>Sodium Oxybate Versus Midazolam for Comfort Sedation</brief_title>
  <acronym>ONAMI</acronym>
  <official_title>Sodium Oxybate Versus Midazolam for Comfort Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at deepen the proof level of sodium oxybate use for comfort sedation at the&#xD;
      end of life in a palliative care unit by comparing it to midazolam in a prospective&#xD;
      randomized study with blinded efficacy evaluation. The study will be carried out for a period&#xD;
      of 24 months with a recruitment objective of 22 patients with refractory suffering and with a&#xD;
      short-term prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In certain cases, terminally-ill patients may show persistent symptoms despite numerous&#xD;
      efforts to find a comfort treatment without causing impaired consciousness. In these cases&#xD;
      and after a collegial discussion, sedation may be offered.&#xD;
&#xD;
      Midazolam is then the most typically used sedative agent. However, it has limitations:&#xD;
      frequent awakenings, tolerance and major respiratory depression. Furthermore, the use of&#xD;
      midazolam as a &quot;gold standard&quot; in palliative sedation at the end of life falls under expert&#xD;
      consensus without a high level of evidence.&#xD;
&#xD;
      Sodium oxybate (GammaOH®), is an ancient molecule used in anesthesia and other medical&#xD;
      fields. It appears to be an attractive alternative to midazolam. Study hypothesis is as&#xD;
      follows: deep sedation induced by sodium oxybate (RASS: -4 or -5) is more constant and&#xD;
      sustainable than by using midazolam which can cause fluctuating effects and requires frequent&#xD;
      dosage adjustments. The single-blind clinical trial aims at comparing the possibility to&#xD;
      obtain constant deep sedation using midazolam or sodium oxybate. Before the induction, the&#xD;
      patient is not aware of the medication used. The medical team must be aware of it because the&#xD;
      two administration procedures are too different.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants won't be aware of the sedative treatment administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reaching and maintaining a comfort sedation defined by a target RASS score of -4</measure>
    <time_frame>From inclusion until death, up to 12 hours</time_frame>
    <description>Treatment is defined as successful when reaching and consistently maintaining the target score; treatment is defined as not successful when not reaching the target score at induction or not maintaining a score of &lt;= -4 for patients who initially reached the target.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From inclusion until death, up to 12 hours</time_frame>
    <description>Number of clinical adverse events recorded in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>From inclusion until death, up to 12 hours</time_frame>
    <description>Time span between induction of sedation and death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Sodium oxybate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Oxybate injection</intervention_name>
    <description>Induction dosage : 60 mg/kg by direct intravenous injection.&#xD;
Continuous dosage : 45 mg/kg/h by continuous intravenous injection.&#xD;
Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.&#xD;
Sedation maintained until patient death.</description>
    <arm_group_label>Sodium oxybate</arm_group_label>
    <other_name>Gamma-Hydroxybutyric acid</other_name>
    <other_name>4-hydroxybutanoic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam injection</intervention_name>
    <description>Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).&#xD;
Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.&#xD;
Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).&#xD;
Sedation maintained until patient death.</description>
    <arm_group_label>Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient hospitalized in a palliative care unit&#xD;
&#xD;
          -  patient aged 18 or over&#xD;
&#xD;
          -  patient with an estimated vital prognosis of a few hours to a few days*&#xD;
&#xD;
          -  patient with persistent suffering despite optimal palliative care*&#xD;
&#xD;
          -  patient gave informed consent in advance or if unable to do so, consent given by a&#xD;
             family member or legal representative (patients under guardianship)&#xD;
&#xD;
          -  patient covered by a social security scheme. * Validated after collegial and&#xD;
             multidisciplinary discussion including the opinion of a doctor outside the palliative&#xD;
             care team.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication or known allergy to sodium oxybate or midazolam&#xD;
&#xD;
          -  significant risk of seizure&#xD;
&#xD;
          -  venous access not possible&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  person in exclusion period from another research protocol at the time of consent&#xD;
             signing&#xD;
&#xD;
          -  any condition which in the investigator's opinion could increase and jeopardize&#xD;
             persons safety in case of research participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François CIAIS, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Princesse Grace - Monaco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa Jobic</last_name>
    <phone>04 94 14 55 19</phone>
    <phone_ext>+33</phone_ext>
    <email>asmaa.jobic@ch-toulon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François CIAIS, MD</last_name>
      <phone>0797988392</phone>
      <phone_ext>+37</phone_ext>
      <email>jean-françois.ciais@chpg.mc</email>
    </contact>
  </location>
  <location_countries>
    <country>Monaco</country>
  </location_countries>
  <reference>
    <citation>Ciais JF, Jacquin PH, Pradier C, Castelli-Prieto M, Baudin S, Tremellat F. Using Sodium Oxybate (Gamma Hydroxybutyric Acid) for Deep Sedation at the End of Life. J Palliat Med. 2015 Oct;18(10):822. doi: 10.1089/jpm.2015.0221. Epub 2015 Aug 24.</citation>
    <PMID>26302340</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>End-of-life</keyword>
  <keyword>Palliative care</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Sodium oxybate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Sodium Oxybate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

